

Publication List

1. Årdal C, Baraldi E, Busse R, Castro R, Ciabuschi F, Cisneros JM, et al. Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation. *Lancet*. 2024;403(10422):e2-e4.
2. Danielsen AS, Elstrøm P, Eriksen-Volle HM, Hofvind S, Eyre DW, Kacelnik O, et al. The epidemiology of multidrug-resistant organisms in persons diagnosed with cancer in Norway, 2008-2018: expanding surveillance using existing laboratory and register data. *Eur J Clin Microbiol Infect Dis*. 2024;43(1):121-32.
3. Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, et al. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. *Euro Surveill*. 2023;28(33).
4. Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. *Int J Infect Dis*. 2023;130:182-8.
5. Utheim MN, Gawad M, Nygård K, Macdonald E, Falk M. Assessing public health preparedness and response in the European Union- a review of regional simulation exercises and after action reviews. *Global Health*. 2023;19(1):79.
6. Skagseth H, Jørgensen SB, Reilly J, Kacelnik O. A new method for near real-time, nationwide surveillance of nosocomial COVID-19 in Norway: providing data at all levels of the healthcare system, March 2020 to March 2022. *Euro Surveill*. 2023;28(12).
7. Skagseth H, Danielsen AS, Kacelnik O, Trondsen UJ, Berg TC, Sorknes NK, et al. Clusters of healthcare-associated SARS-CoV-2 infections in Norwegian hospitals detected by a fully automatic register-based surveillance system. *J Hosp Infect*. 2023;135:50-4.
8. Saegerman C, Humblet MF, Leandri M, Gonzalez G, Heyman P, Sprong H, et al. First Expert Elicitation of Knowledge on Possible Drivers of Observed Increasing Human Cases of Tick-Borne Encephalitis in Europe. *Viruses*. 2023;15(3).
9. Rotevatn TA, Nygård K, Espenhain L, Legarth R, Møller KL, Sarvikivi E, et al. When schools were open for in-person teaching during the COVID-19 pandemic - the nordic experience on control measures and transmission in schools during the delta wave. *Bmc Public Health*. 2023;23(1):62.
10. Plachouras D, Kacelnik O, Rodríguez-Baño J, Birgand G, Borg MA, Kristensen B, et al. Revisiting the personal protective equipment components of transmission-based precautions for the prevention of COVID-19 and other respiratory virus infections in healthcare. *Euro Surveill*. 2023;28(32).
11. Nyberg T, Bager P, Svalgaard IB, Bejko D, Bundle N, Evans J, et al. A standardised protocol for relative SARS-CoV-2 variant severity assessment, applied to Omicron BA.1 and Delta in six European countries, October 2021 to February 2022. *Eurosurveillance*. 2023;28(36):2300048.
12. Mekonnen Z, Melaku T, Tucho GT, Mecha M, Årdal C, Jahre M. The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study. *BMC Health Serv Res*. 2023;23(1):513.
13. McFarland SE, Marcus U, Hemmers L, Miura F, Iñigo Martínez J, Martínez FM, et al. Estimated incubation period distributions of mpox using cases from two international European festivals and outbreaks in a club in Berlin, May to June 2022. *Euro Surveill*. 2023;28(27).
14. Ljungquist O, Haldorsen B, Pöntinen AK, Janice J, Josefsen EH, Elstrøm P, et al. Nationwide, population-based observational study of the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in Norway, 2015 to 2021. *Euro Surveill*. 2023;28(27).
15. Lindemann PC, Pedersen T, Oma DH, Janice J, Grøvan F, Chedid GM, et al. Intraregional hospital outbreak of OXA-244-producing *Escherichia coli* ST38 in Norway, 2020. *Euro Surveill*. 2023;28(27).

16. Langlete P, Tesli M, Veneti L, Starrfelt J, Elstrøm P, Meijerink H. Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022. *Vaccine*. 2023;41(26):3923-9.
17. Jore S, Viljugrein H, Hjertqvist M, Dub T, Mäkelä H. Outdoor recreation, tick borne encephalitis incidence and seasonality in Finland, Norway and Sweden during the COVID-19 pandemic (2020/2021). *Infection Ecology & Epidemiology*. 2023;13(1):2281055.
18. Goren A, Viljugrein H, Rivrud IM, Jore S, Bakka H, Vindenes Y, et al. The emergence and shift in seasonality of Lyme borreliosis in Northern Europe. *Proc Biol Sci*. 2023;290(1993):20222420.
19. Goren A, Mysterud A, Jore S, Viljugrein H, Bakka H, Vindenes Y. Demographic patterns in Lyme borreliosis seasonality over 25 years. *Zoonoses Public Health*. 2023;70(7):647-55.
20. Franconeri L, Stebbings S, Heradstveit P, Johansen M, Løken R, MacDonald E, et al. Experiences with regular testing of students for SARS-CoV-2 in primary and secondary schools: results from a cross-sectional study in two Norwegian counties, autumn 2021. *Bmc Public Health*. 2023;23(1):1548.
21. Baz Lomba JA, Pires J, Myrmed M, Arnø JK, Madslie EH, Langlete P, et al. Effectiveness of environmental surveillance of SARS-CoV-2 as an early-warning system: Update of a systematic review during the second year of the pandemic. *J Water Health*. 2023.
22. Amato E, Hyllestad S, Heradstveit P, Langlete P, Moen LV, Rohringer A, et al. Evaluation of the pilot wastewater surveillance for SARS-CoV-2 in Norway, June 2022 – March 2023. *Bmc Public Health*. 2023;23(1):1714.
23. Al Rubaye M, Janice J, Bjørnholt JV, Kacelnik O, Haldorsen BC, Nygaard RM, et al. The population structure of vancomycin-resistant and -susceptible *Enterococcus faecium* in a low-prevalence antimicrobial resistance setting is highly influenced by circulating global hospital-associated clones. *Microb Genom*. 2023;9(12).
24. Ahlqvist V, Dube N, Jahre M, Lee JS, Melaku T, Moe AF, et al. Supply chain risk management strategies in normal and abnormal times: policymakers' role in reducing generic medicine shortages. *International Journal of Physical Distribution & Logistics Management*. 2023;53(2):206-30.
25. Aarø LE, Veneti L, Vedaa Ø, Smith ORF, De Blasio BF, Robberstad B. Visiting crowded places during the COVID-19 pandemic. A panel study among adult Norwegians. *Front Public Health*. 2022;10:1076090.
26. Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes E, Kløvstad H, et al. The surveillance of patients hospitalised with COVID-19 in Norway: a comparison of two register-based systems. 2022.
27. Whittaker R, Greve-Isdahl M, Bøås H, Suren P, Buanes EA, Veneti L. COVID-19 hospitalization among children < 18 years by variant wave in Norway. *Pediatrics*. 2022;150(3):e2022057564.
28. Veneti L, Salamanca BV, Seppälä E, Starrfelt J, Storm ML, Bragstad K, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. *Int J Infect Dis*. 2022;115:178-84.
29. Veneti L, Bøås H, Kristoffersen AB, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. *Eurosurveillance*. 2022;27(4):2200077.
30. Vaughan AM, Cenciarelli O, Colombe S, Alves de Sousa L, Fischer N, Gossner CM, et al. A large multi-country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022. *Euro Surveill*. 2022;27(36):2200620.
31. Utheim MN, Gawad M, Macdonald E, Nygård K, Bengtsson S, Falk M. Assessing public health preparedness and response in the EU A review of EU-level Simulation Exercises and After Action Reviews. 2022.
32. Tscherne A, Mantel E, Boskani T, Budniak S, Elschner M, Fasanella A, et al. Adaptation of *Brucella melitensis* Antimicrobial Susceptibility Testing to the ISO 20776 Standard and Validation of the Method. *Microorganisms*. 2022;10(7):1470.

33. Thaulow CM, Harthug S, Nilsen RM, Eriksen BH, Wathne JS, Berild D, et al. Are infants exposed to antimicrobials during the first 3 months of life at increased risk of recurrent use? An explorative data-linkage study. *Journal of Antimicrobial Chemotherapy*. 2022;77(5):1468-75.
34. Thaulow CM, Blix HS, Nilsen RM, Eriksen BH, Wathne JS, Berild D, et al. Antibiotic use in children before, during and after hospitalisation. *Pharmacoepidem Dr S*. 2022;31(7):749-57.
35. Thaulow CM, Blix HS, Eriksen BH, Ask I, Myklebust TÅ, Berild D. Using a period incidence survey to compare antibiotic use in children between a university hospital and a district hospital in a country with low antimicrobial resistance: a prospective observational study. *BMJ open*. 2022;9(5):e027836.
36. Stålcrantz J, Kristoffersen AB, Bøås H, Veneti L, Seppälä E, Aasand N, et al. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway. *Scandinavian Journal of Public Health*. 2022;50(6):676-82.
37. Stebbings S, Rotevatn TA, Larsen VB, Suren P, Elstrom P, Greve-Isdahl M, et al. Experience with open schools and preschools in periods of high community transmission of COVID-19 in Norway during the academic year of 2020/2021. *Bmc Public Health*. 2022;22(1):1454.
38. Starrfelt J, Danielsen AS, Kacelnik O, Wang Børseth A, Seppälä E, Meijerink H. High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020-June 2021. *Antimicrob Steward Healthc Epidemiol*. 2022;2(1):e10.
39. Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø GØI, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021. *Bmc Med*. 2022;20(1):278.
40. Skaland RG, Herrador BG, Hisdal H, Hygen HO, Hyllestad S, Lund V, et al. Impacts of climate change on drinking water quality in Norway. *J Water Health*. 2022;20(3):539-50.
41. Severi E, Georgalis L, Pijnacker R, Veneti L, Turicac IA, Chiesa F, et al. Severity of the clinical presentation of hepatitis A in five European countries from 1995 to 2014. *Int J Infect Dis*. 2022;118:34-43.
42. Rotevatn TA, Elstrom P, Greve-Isdahl M, Suren P, Johansen TKB, Astrup E. School Closure Versus Targeted Control Measures for SARS-CoV-2 Infection. *Pediatrics*. 2022;149(5):e2021055071.
43. Rotevatn TA, Bergstad Larsen V, Bjordal Johansen T, Astrup E, Suren P, Greve-Isdahl M, et al. Transmission of SARS-CoV-2 in Norwegian schools during academic year 2020-21: population wide, register based cohort study. *BMJ Med*. 2022;1(1):e000026.
44. Peñalva-Moreno G, Crespo-Robledo P, Molvik M, López-Navas A, Kacelnik O, Cisneros JM. A step forward in antibiotic use and resistance monitoring: a quarterly surveillance system pilot in 11 European Union/European Economic Area countries, September 2017 to May 2020. 2022.
45. Oxman AD, Fretheim A, Lewin S, Flottorp S, Glenton C, Helleve A, et al. Health communication in and out of public health emergencies: to persuade or to inform? *Health Res Policy Syst*. 2022;20(1):28.
46. Methi F, Madslie EH. Lower transmissibility of SARS-CoV-2 among asymptomatic cases: evidence from contact tracing data in Oslo, Norway. *Bmc Med*. 2022;20(1):1-9.
47. Lindstrom JC, Engebretsen S, Kristoffersen AB, Ro GOI, Palomares AD, Engo-Monsen K, et al. Increased transmissibility of the alpha SARS-CoV-2 variant: evidence from contact tracing data in Oslo, January to February 2021. *Infect Dis (Lond)*. 2022;54(1):72-7.
48. Labberton AS, Godoy A, Elgersma IH, Strand BH, Telle K, Arnesen T, et al. SARS-CoV-2 infections and hospitalisations among immigrants in Norway-significance of occupation, household crowding, education, household income and medical risk: a nationwide register study. *Scandinavian Journal of Public Health*. 2022;50(6):772-81.
49. Kraft KB, Elgersma I, Lyngstad TM, Elstrøm P, Telle K. COVID-19 vaccination rates among healthcare workers by immigrant background: A nation-wide registry study from Norway. *Scandinavian Journal of Public Health*. 2022:14034948221100685.
50. Kacelnik O, Kacelnik A. Behavioral risk compensation and the efficacy of nonpharmacological interventions. *Behav Public Policy*. 2022;6(1):1-12.

51. Jorgensen SB, Nygard K, Kacelnik O, Telle K. Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households. *JAMA*. 2022;327(16):1610-1.
52. Jore S, Braae UC, Trier Moller F, Friesema I, Paranthaman K, Jalava K, et al. A common framework for using and reporting consumer purchase data (CPD) in foodborne outbreak investigations in Europe. *Infect Ecol Epidemiol*. 2022;12(1):2007828.
53. Jalali N, Brustad HK, Frigessi A, MacDonald EA, Meijerink H, Feruglio SL, et al. Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants. *Nat Commun*. 2022;13(1):5706.
54. Hyllestad S, Myrmet M, Lomba JAB, Jordhoy F, Schipper SK, Amato E. Effectiveness of environmental surveillance of SARS-CoV-2 as an early warning system during the first year of the COVID-19 pandemic: a systematic review. *J Water Health*. 2022;20(8):1223-42.
55. Gravningen K, Kacelnik O, Lingaas E, Pedersen T, Iversen BG, Pseudomonas outbreak g. *Pseudomonas aeruginosa* countrywide outbreak in hospitals linked to pre-moistened non-sterile washcloths, Norway, October 2021 to April 2022. *Euro Surveill*. 2022;27(18):2200312.
56. Gravningen K, Henriksen S, Hungnes O, Svendsen K, MacDonald E, Schirmer H, et al. Risk factors, immune response and whole-genome sequencing of SARS-CoV-2 in a cruise ship outbreak in Norway. *Int J Infect Dis*. 2022;118:10-20.
57. Fretheim A, Elgersma IH, Helleve A, Elstrom P, Kacelnik O, Hemkens LG. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(12):e2244495.
58. Enger H, Larssen KW, Damas ES, Aamot HV, Blomfeldt A, Elstrom P, et al. A tale of two STs: molecular and clinical epidemiology of MRSA t304 in Norway 2008-2016. *Eur J Clin Microbiol Infect Dis*. 2022;41(2):209-18.
59. Dougherty PE, Moller FT, Ethelberg S, Ro GOI, Jore S. Simulation and identification of foodborne outbreaks in a large supermarket consumer purchase dataset. *Sci Rep*. 2022;12(1):11491.
60. Danielsen AS, Franconeri L, Page S, Myhre AE, Tornes RA, Kacelnik O, et al. Risk factor modelling of antimicrobial resistance in cancer patients: A systematic review. 2022.
61. Brandal LT, Vestheim DF, Bruvik T, Roness RB, Bjornstad ML, Greve-Isdahl M, et al. Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019. *Eur J Clin Microbiol Infect Dis*. 2022;41(6):913-24.
62. Amato E, Riess M, Thomas-Lopez D, Linkevicius M, Pitkanen T, Wolkowicz T, et al. Epidemiological and microbiological investigation of a large increase in vibriosis, northern Europe, 2018. *Euro Surveill*. 2022;27(28):2101088.
63. Whittaker R, Kristofferson AB, Seppala E, Valcarcel Salamanca B, Veneti L, Storm ML, et al. Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 - April 2021. *J Infect*. 2021;83(4):e14-e7.
64. Veneti L, Seppala E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. *PLoS One*. 2021;16(10):e0258513.
65. Telle K, Jorgensen SB, Hart R, Greve-Isdahl M, Kacelnik O. Secondary attack rates of COVID-19 in Norwegian families: a nation-wide register-based study. *Eur J Epidemiol*. 2021;36(7):741-8.
66. Seppala E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, et al. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. *Euro Surveill*. 2021;26(35):2100793.
67. Robertson LJ, Jore S, Lund V, Grahek-Ogden D. Risk assessment of parasites in Norwegian drinking water: opportunities and challenges. *Food Waterb Parasit*. 2021;22:e00112.
68. Ramstad SN, Wasteson Y, Lindstedt BA, Taxt AM, Bjornholt JV, Brandal LT, et al. Characterization of Shiga Toxin 2a Encoding Bacteriophages Isolated From High-Virulent O145:H25 Shiga Toxin-Producing Escherichia coli. *Front Microbiol*. 2021;12:728116.

69. Ramstad SN, Taxt AM, Naseer U, Wasteson Y, Bjornholt JV, Brandal LT. Effects of antimicrobials on Shiga toxin production in high-virulent Shiga toxin-producing *Escherichia coli*. *Microb Pathog*. 2021;152:104636.
70. Ramstad SN, Brandal LT, Taxt AM, Wasteson Y, Bjornholt JV, Naseer U. Prevalence of genotypic antimicrobial resistance in clinical Shiga toxin-producing *Escherichia coli* in Norway, 2018 to 2020. *J Med Microbiol*. 2021;70(12).
71. Outtersen K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020. *Clinical Infectious Diseases*. 2021;74(7):1183-90.
72. Meijerink H, Mauroy C, Johansen MK, Braaten SM, Lunde CUS, Arnesen TM, et al. The first GAEN-based COVID-19 contact tracing app in Norway identifies 80% of close contacts in “real life” scenarios. *Frontiers in digital health*. 2021;3:731098.
73. Magnusson K, Nygard K, Methi F, Vold L, Telle K. Occupational risk of COVID-19 in the first versus second epidemic wave in Norway, 2020. *Euro Surveill*. 2021;26(40):2001875.
74. Løvdal T, Brandal LT, Sundaram AY, Naseer U, Roth B, Lunestad BT. Small-scale comparative genomic analysis of *Listeria monocytogenes* isolated from environments of salmon processing plants and human cases in Norway. *Hygiene*. 2021;1(1):43-55.
75. Johansen TB, Brandal LT, MacDonald E, Naseer U, Stefanoff P, Roed MH, et al. Exotic dried fruits caused *Salmonella* Agbeni outbreak with severe clinical presentation, Norway, December 2018 to March 2019. *Euro Surveill*. 2021;26(14):2000221.
76. Indseth T, Grosland M, Arnesen T, Skyrud K, Klovstad H, Lamprini V, et al. COVID-19 among immigrants in Norway, notified infections, related hospitalizations and associated mortality: A register-based study. *Scandinavian Journal of Public Health*. 2021;49(1):48-56.
77. Hyllestad S, Kjorsvik SS, Veneti L, Amato E. Identifying challenges in drinking water supplies: assessment of boil water advisories in Norway (2008-2019). *J Water Health*. 2021;19(5):872-84.
78. Hyllestad S, Amato E, Nygard K, Vold L, Aavitsland P. The effectiveness of syndromic surveillance for the early detection of waterborne outbreaks: a systematic review. *BMC Infect Dis*. 2021;21(1):696.
79. Herrador BG, Lund V, Fonahn W, Hisdal H, Hygen HO, Hyllestad S, et al. Heavy weather events, water quality and gastroenteritis in Norway. *One Health*. 2021;13:100297.
80. Danielsen AS, Cyr PR, Magnus MC, Gravningen KM, Eriksen-Volle HM, Kacelnik O. Birthing parents had a lower risk of testing positive for SARS-CoV-2 in the peripartum period in Norway, 15th of February 2020 to 15th of May 2021. *Infect Prev Pract*. 2021;3(4):100183.
81. Buschhardt T, Gunther T, Skjerdal T, Torpdahl M, Gethmann J, Filippitzi ME, et al. A one health glossary to support communication and information exchange between the human health, animal health and food safety sectors. *One Health*. 2021;13:100263.
82. Brandal LT, Ofitserova TS, Meijerink H, Rykkvin R, Lund HM, Hungnes O, et al. Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020. *Euro Surveill*. 2021;26(1):2002011.
83. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro Surveill*. 2021;26(50):2101147.
84. Avershina E, Sharma P, Taxt AM, Singh H, Frye SA, Paul K, et al. AMR-Diag: Neural network based genotype-to-phenotype prediction of resistance towards beta-lactams in *Escherichia coli* and *Klebsiella pneumoniae*. *Comput Struct Biotechnol J*. 2021;19:1896-906.
85. Askeland Winje B, Ofitserova TS, Brynildsrud OB, Greve-Isdahl M, Bragstad K, Rykkvin R, et al. Comprehensive contact tracing, testing and sequencing show limited transmission of sars-cov-2 between children in schools in Norway, August 2020 to May 2021. 2021.
86. Ardal C, McAdams D, Wester AL, Mogedal S. Adapting environmental surveillance for polio to the need to track antimicrobial resistance. *Bull World Health Organ*. 2021;99(3):239-40.

87. Ardal C, Lacotte Y, Edwards S, Ploy MC, On Behalf Of The European Union Joint Action On Antimicrobial R, Healthcare-Associated Infections E-J. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation. *Antibiotics (Basel)*. 2021;10(6):749.
88. Ardal C, Baraldi E, Beyer P, Lacotte Y, Larsson DJ, Ploy MC, et al. Supply chain transparency and the availability of essential medicines. *Bull World Health Organ*. 2021;99(4):319-20.
89. van Oort BEH, Hovelsrud GK, Risvoll C, Mohr CW, Jore S. A Mini-Review of Ixodes Ticks Climate Sensitive Infection Dispersion Risk in the Nordic Region. *Int J Env Res Pub He*. 2020;17(15).
90. Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R. Rapid identification of pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencing. *Sci Rep*. 2020;10(1):7622.
91. Stefanoff P, Lovlie AL, Elstrom P, Macdonald EA. Reporting of notifiable infectious diseases during the COVID-19 response. *Tidsskr Nor Laegeforen*. 2020;140(9).
92. Steens A, Freiesleben de Blasio B, Veneti L, Gimma A, Edmunds WJ, Van Zandvoort K, et al. Poor self-reported adherence to COVID-19-related quarantine/isolation requests, Norway, April to July 2020. *Euro Surveill*. 2020;25(37):2001607.
93. Seppala E, Tonnessen R, Veneti L, Paulsen TH, Steens A, Whittaker R, et al. COVID-19 cases reported to the Norwegian Institute of Public Health in the first six weeks of the epidemic. *Tidsskr Nor Laegeforen*. 2020;140(18).
94. Nystad W, Hjellvik V, Larsen IK, Ariansen I, Helland E, Johansen KI, et al. Underlying conditions in adults with COVID-19. *Tidsskr Nor Laegeforen*. 2020;140(13).
95. Lacotte Y, Årdal C, Ploy M-C, Resistance EUJAOA, Infections H-A. Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? Results of a narrative literature review and survey analysis. *Antimicrobial Resistance & Infection Control*. 2020;9:1-10.
96. Kuhn KG, Nygård KM, Guzman-Herrador B, Sunde LS, Rimhanen-Finne R, Trönnberg L, et al. *Campylobacter* infections expected to increase due to climate change in Northern Europe. *Sci Rep-Uk*. 2020;10(1):13874.
97. Jore S, Vanwambeke SO, Slunge D, Boman A, Krogfelt KA, Jepsen MT, et al. Spatial tick bite exposure and associated risk factors in Scandinavia. *Infect Ecol Epidemiol*. 2020;10(1):1764693.
98. Johansen TB, Astrup E, Jore S, Nilssen H, Dahlberg BB, Klingenberg C, et al. Infection prevention guidelines and considerations for paediatric risk groups when reopening primary schools during COVID-19 pandemic, Norway, April 2020. *Eurosurveillance*. 2020;25(22):8-13.
99. Hyllestad S, Lund V, Nygard K, Aavitsland P, Vold L. The establishment and first experiences of a crisis advisory service for water supplies in Norway. *J Water Health*. 2020;18(4):545-55.
100. Hyllestad S, Iversen A, MacDonald E, Amato E, Borge BAS, Boe A, et al. Large waterborne *Campylobacter* outbreak: use of multiple approaches to investigate contamination of the drinking water supply system, Norway, June 2019. *Euro Surveill*. 2020;25(35):2000011.
101. Haugnes H, Elstrom P, Kacelnik O, Jadcak U, Wisloff T, de Blasio BF. Financial and temporal costs of patient isolation in Norwegian hospitals. *J Hosp Infect*. 2020;104(3):269-75.
102. Hauge SH, Meijerink H, Alveberg BL, Berg AS, Bergh A, Bragstad K, et al. Urbanization and preparedness for outbreaks with high-impact respiratory pathogens. 2020.
103. Gravningen K, Field N, Blix HS, Asfeldt AM, Småbrekke L. Non-prescription purchase of antibiotics during travel abroad among a general adult population in Norway: Findings from the seventh Tromsø Study. *PLOS ONE*. 2020;15(2):e0228792.
104. Gossner CM, Mailles A, Aznar I, Dimina E, Echevarria JE, Feruglio SL, et al. Prevention of human rabies: a challenge for the European Union and the European Economic Area. *Euro Surveill*. 2020;25(38):2000158.
105. Franer K, Meijerink H, Hyllestad S. Compliance with a boil water advisory after the contamination of a municipal drinking water supply system in Norway. *J Water Health*. 2020;18(6):1084-90.

106. Ardal C, Lacotte Y, Ploy MC. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe. *Clin Infect Dis*. 2020;71(8):1994-9.
107. Ardal C, Balasegaram M, Laxminarayan R, McAdams D, Outtersson K, Rex JH, et al. Antibiotic development - economic, regulatory and societal challenges. *Nat Rev Microbiol*. 2020;18(5):267-74.
108. Wolff C, Lange H, Feruglio S, Vold L, MacDonald E. Evaluation of the national surveillance of Legionnaires' disease in Norway, 2008-2017. *Bmc Public Health*. 2019;19(1):1624.
109. Veneti L, Lange H, Brandal L, Danis K, Vold L. Mapping of control measures to prevent secondary transmission of STEC infections in Europe during 2016 and revision of the national guidelines in Norway. *Epidemiol Infect*. 2019;147:e267.
110. Slunge D, Jore S, Krogfelt KA, Jepsen MT, Boman A. Who is afraid of ticks and tick-borne diseases? Results from a cross-sectional survey in Scandinavia. *Bmc Public Health*. 2019;19(1):1666.
111. Siira L, Naseer U, Alfsnes K, Hermansen NO, Lange H, Brandal LT. Whole genome sequencing of *Salmonella* Chester reveals geographically distinct clusters, Norway, 2000 to 2016. *Euro Surveill*. 2019;24(4):1800186.
112. Siira L, MacDonald E, Holmbakken GM, Sundar T, Meyer-Myklestad L, Lange H, et al. Increasing incubation periods during a prolonged monophasic Typhimurium outbreak with environmental contamination of a commercial kitchen at Oslo Airport, Norway, 2017. *Eurosurveillance*. 2019;24(34):17-23.
113. Pijnacker R, Dallman TJ, Tijmsa ASL, Hawkins G, Larkin L, Kotila SM, et al. An international outbreak of *Salmonella enterica* serotype Enteritidis linked to eggs from Poland: a microbiological and epidemiological study. *Lancet Infect Dis*. 2019;19(7):778-86.
114. Mysterud A, Heylen DJA, Matthysen E, Garcia AL, Jore S, Viljugrein H. Lyme neuroborreliosis and bird populations in northern Europe. *Proc Biol Sci*. 2019;286(1903):20190759.
115. MacDonald E, White R, Mexial R, Bruun T, Kapperud G, Brandal LT, et al. The role of domestic reservoirs in domestically acquired infections in Norway: epidemiology of salmonellosis, 2000-2015, and results of a national prospective case-control study, 2010-2012. *Epidemiol Infect*. 2019;147:e43.
116. Langlete P, Krabberød AK, Winther-Larsen HC. Vesicles from *Vibrio cholerae* contain AT-rich DNA and shorter mRNAs that do not correlate with their protein products. *Frontiers in Microbiology*. 2019;10:2708.
117. Kållberg C, Salvesen Blix H, Laxminarayan R. Challenges in antibiotic R&D calling for a global strategy considering both short-and long-term solutions. *ACS Infectious Diseases*. 2019;5(8):1265-8.
118. Johansen TB, Klovstad H, Rykkvin R, Herrfurth-Erichsen EB, Sorthe J, Njolstad G, et al. The 'Finnish new variant of 'escaping detection in the Aptima Combo 2 assay is widespread across Norway, June to August 2019. *Eurosurveillance*. 2019;24(42):2-6.
119. Jenssen GR, Veneti L, Lange H, Vold L, Naseer U, Brandal LT. Implementation of multiplex PCR diagnostics for gastrointestinal pathogens linked to increase of notified Shiga toxin-producing *Escherichia coli* cases in Norway, 2007-2017. *Eur J Clin Microbiol Infect Dis*. 2019;38(4):801-9.
120. Hyllestad S, Veneti L, Bugge AB, Rosenberg TG, Nygard K, Aavitsland P. Compliance with water advisories after water outages in Norway. *Bmc Public Health*. 2019;19(1):1188.
121. Hyllestad S, Lange H, Guzman-Herrador B, MacDonald E, Lund V, Aavitsland P, et al. An outbreak of skin rash traced to a portable floating tank in Norway, May 2017. *Euro Surveill*. 2019;24(38):1900134.
122. Hansen H, Kapperud G, Mysterud A, Solberg EJ, Strand O, Tranulis M, et al. CWD in Norway—a state of emergency for the future of cervids (Phase II). 2019.
123. Espenhain L, Berg TC, Bentele H, Nygard K, Kacelnik O. Epidemiology and impact of norovirus outbreaks in Norwegian healthcare institutions, 2005-2018. *J Hosp Infect*. 2019;103(3):335-40.
124. Elstrøm P, Astrup E, Hegstad K, Samuelson Ø, Enger H, Kacelnik O. The fight to keep resistance at bay, epidemiology of carbapenemase producing organisms (CPOs), vancomycin

- resistant enterococci (VRE) and methicillin resistant *Staphylococcus aureus* (MRSA) in Norway, 2006-2017. *PLoS One*. 2019;14(2):e0211741.
125. Elstrom P, Grontvedt CA, Gabrielsen C, Stegger M, Angen O, Amdal S, et al. Livestock-Associated MRSA CC1 in Norway; Introduction to Pig Farms, Zoonotic Transmission, and Eradication. *Front Microbiol*. 2019;10:139.
126. Dorj G, Blix HS, Sunderland B, Gankhulug B, Tegshee O, Purevkhoo M, et al. Antibiotic Utilization Trends in Two State Hospitals of Mongolia from 2013 to 2017. *Biomed Res Int-Uk*. 2019;2019:1-8.
127. Dansie LS, Odoch WD, Årdal C. Industrial perceptions of medicines regulatory harmonization in the East African Community. *PLOS ONE*. 2019;14(6):e0218617.
128. Danielsen AS, Elstrom P, Arnesen TM, Gopinathan U, Kacelnik O. Targeting TB or MRSA in Norwegian municipalities during 'the refugee crisis' of 2015: a framework for priority setting in screening. *Eurosurveillance*. 2019;24(38):24-32.
129. Amato E, Dansie LS, Grøneng GM, Blix HS, Bentele H, Veneti L, et al. Increase of scabies infestations, Norway, 2006 to 2018. *Euro Surveill*. 2019;24(23).
130. Årdal C, Baraldi E, Theuretzbacher U, Outtersen K, Plahte J, Ciabuschi F, et al. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. *J Pharm Policy Pract*. 2018;11:8.
131. Årdal C, Baraldi E, Theuretzbacher U, Outtersen K, Plahte J, Ciabuschi F, et al. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. *Journal of pharmaceutical policy and practice*. 2018;11(1):1-10.
132. Veneti L, Borgen K, Borge KS, Danis K, Greve-Isdahl M, Konsmo K, et al. Large outbreak of mumps virus genotype G among vaccinated students in Norway, 2015 to 2016. *Eurosurveillance*. 2018;23(38):14-22.
133. Savic M, Årdal C. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics. *J Law Med Ethics*. 2018;46(S1):9-24.
134. M'Bangombe M, Pezzoli L, Reeder B, Kabuluzi S, Msyamboza K, Masuku H, et al. Oral cholera vaccine in cholera prevention and control, Malawi. *Bull World Health Organ*. 2018;96(6):428-35.
135. Lindstedt BA, Finton MD, Porcellato D, Brandal LT. High frequency of hybrid *Escherichia coli* strains with combined Intestinal Pathogenic *Escherichia coli* (IPEC) and Extraintestinal Pathogenic *Escherichia coli* (ExPEC) virulence factors isolated from human faecal samples. *BMC Infect Dis*. 2018;18(1):544.
136. Kållberg C, Årdal C, Salvesen Blix H, Klein E, M. Martinez E, Lindbæk M, et al. Introduction and geographic availability of new antibiotics approved between 1999 and 2014. *PLoS one*. 2018;13(10):e0205166.
137. Johansen TB, Scheffer L, Jensen VK, Bohlin J, Feruglio SL. Whole-genome sequencing and antimicrobial resistance in *Brucella melitensis* from a Norwegian perspective. *Sci Rep*. 2018;8(1):8538.
138. Beaute J, Westrell T, Schmid D, Muller L, Epstein J, Kontio M, et al. Travel-associated hepatitis A in Europe, 2009 to 2015. *Euro Surveill*. 2018;23(22):1700583.
139. Baraldi E, Lindahl O, Savic M, Findlay D, Årdal C. Antibiotic Pipeline Coordinators. *J Law Med Ethics*. 2018;46(1_suppl):25-31.
140. Årdal C, Johnsen J, Johansen K. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway. *J Law Med Ethics*. 2018;46(1_suppl):43-9.